Business Description
RaySearch Laboratories AB
ISIN : SE0000135485
Share Class Description:
CHIX:RAYBs: Class BDescription
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia Pacific, Europe and the rest of the world.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.12 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.49 | |||||
| Debt-to-EBITDA | 1.55 | |||||
| Interest Coverage | 39.63 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 7.81 | |||||
| Beneish M-Score | -2.91 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 22.9 | |||||
| 3-Year EBITDA Growth Rate | 42.5 | |||||
| 3-Year Book Growth Rate | 11.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.33 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.65 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.76 | |||||
| 9-Day RSI | 89.94 | |||||
| 14-Day RSI | 91.19 | |||||
| 3-1 Month Momentum % | 32.63 | |||||
| 6-1 Month Momentum % | 99.49 | |||||
| 12-1 Month Momentum % | 333.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.53 | |||||
| Quick Ratio | 1.52 | |||||
| Cash Ratio | 0.78 | |||||
| Days Inventory | 53.23 | |||||
| Days Sales Outstanding | 65.94 | |||||
| Days Payable | 119.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.96 | |||||
| Dividend Payout Ratio | 0.11 | |||||
| Forward Dividend Yield % | 0.96 | |||||
| 5-Year Yield-on-Cost % | 0.96 | |||||
| Shareholder Yield % | 1.21 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.88 | |||||
| Operating Margin % | 22.86 | |||||
| Net Margin % | 17.66 | |||||
| EBITDA Margin % | 22.86 | |||||
| FCF Margin % | 19.43 | |||||
| ROE % | 26.92 | |||||
| ROA % | 10.86 | |||||
| ROIC % | 12.56 | |||||
| 3-Year ROIIC % | 671.34 | |||||
| ROC (Joel Greenblatt) % | 55 | |||||
| ROCE % | 21.5 | |||||
| Years of Profitability over Past 10-Year | 8 | |||||
| Moat Score | 5 | |||||
| Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 55.29 | |||||
| Forward PE Ratio | 43.17 | |||||
| PE Ratio without NRI | 55.29 | |||||
| Shiller PE Ratio | 141.56 | |||||
| PEG Ratio | 2.68 | |||||
| PS Ratio | 9.76 | |||||
| PB Ratio | 13.4 | |||||
| Price-to-Tangible-Book | 34.02 | |||||
| Price-to-Free-Cash-Flow | 50.24 | |||||
| Price-to-Operating-Cash-Flow | 26.61 | |||||
| EV-to-EBIT | 42.03 | |||||
| EV-to-EBITDA | 42.03 | |||||
| EV-to-Revenue | 9.61 | |||||
| EV-to-FCF | 50.01 | |||||
| Price-to-GF-Value | 2.37 | |||||
| Price-to-Projected-FCF | 3.05 | |||||
| Price-to-DCF (Earnings Based) | 3.54 | |||||
| Price-to-DCF (FCF Based) | 3.22 | |||||
| Price-to-Median-PS-Value | 1.86 | |||||
| Price-to-Graham-Number | 9.14 | |||||
| Earnings Yield (Greenblatt) % | 2.38 | |||||
| FCF Yield % | 2.01 | |||||
| Forward Rate of Return (Yacktman) % | -13.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RaySearch Laboratories AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 1,266.531 | ||
| EPS (TTM) (kr) | 6.52 | ||
| Beta | 0.23 | ||
| 3-Year Sharpe Ratio | 1.05 | ||
| 3-Year Sortino Ratio | 26.84 | ||
| Volatility % | 124.69 | ||
| 14-Day RSI | 91.19 | ||
| 14-Day ATR (kr) | 0.169152 | ||
| 20-Day SMA (kr) | 313 | ||
| 12-1 Month Momentum % | 333.52 | ||
| 52-Week Range (kr) | 72.2 - 315 | ||
| Shares Outstanding (Mil) | 34.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RaySearch Laboratories AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RaySearch Laboratories AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
RaySearch Laboratories AB Frequently Asked Questions
What is RaySearch Laboratories AB(CHIX:RAYBs)'s stock price today?
The current price of CHIX:RAYBs is kr313.00. The 52 week high of CHIX:RAYBs is kr315.00 and 52 week low is kr72.20.
When is next earnings date of RaySearch Laboratories AB(CHIX:RAYBs)?
The next earnings date of RaySearch Laboratories AB(CHIX:RAYBs) is 2025-08-07.
Does RaySearch Laboratories AB(CHIX:RAYBs) pay dividends? If so, how much?
The Dividend Yield %  of RaySearch Laboratories AB(CHIX:RAYBs) is 0.96% (As of Today), Highest Dividend Payout Ratio of RaySearch Laboratories AB(CHIX:RAYBs) was 0.12. The lowest was 0.06. And the median was 0.09. The  Forward Dividend Yield % of RaySearch Laboratories AB(CHIX:RAYBs) is 0.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers